Open AccessCOVID-19 Vaccine and Biologics: An Impending Dilemma
Author(s) -
Megan Hauptman,
Jelena Vasić,
Jeffrey M. Krase
Publication year - 2020
Publication title -
journal of drugs in dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.701
H-Index - 62
ISSN - 1545-9616
DOI - 10.36849/jdd.5628
Subject(s) - medicine , covid-19 , pandemic , dilemma , intensive care medicine , virology , philosophy , disease , epistemology , outbreak , infectious disease (medical specialty)
The COVID-19 pandemic has forced healthcare providers across all specialties to adjust their methods of clinical practice. In Dermatology, focus on the continued safe usage of immunomodulating biologic therapies has attracted particular interest as the COVID-19 virus represents a novel infection risk. While guidance on biologic initiation and continuation has been established,1 the return to normalcy will likely involve a safe and effective vaccine. This vaccine(s) will represent a new clinical hurdle for prescribers who have continued patients on biologic therapy throughout the pandemic.